nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—colon cancer—breast cancer	0.182	0.538	CtDrD
Methotrexate—bone cancer—breast cancer	0.156	0.462	CtDrD
Methotrexate—SLCO1B1—breast cancer	0.0568	0.255	CbGaD
Methotrexate—ABCC1—breast cancer	0.0469	0.211	CbGaD
Methotrexate—TYMS—breast cancer	0.0406	0.183	CbGaD
Methotrexate—MTHFR—breast cancer	0.0323	0.145	CbGaD
Methotrexate—ABCG2—breast cancer	0.0247	0.111	CbGaD
Methotrexate—TYMS—Capecitabine—breast cancer	0.0194	0.0786	CbGbCtD
Methotrexate—AOX1—Raloxifene—breast cancer	0.0184	0.0747	CbGbCtD
Methotrexate—MTHFR—Fluorouracil—breast cancer	0.0135	0.0547	CbGbCtD
Methotrexate—TYMS—Gemcitabine—breast cancer	0.0134	0.0545	CbGbCtD
Methotrexate—TYMS—Fluorouracil—breast cancer	0.0115	0.0466	CbGbCtD
Methotrexate—ABCC1—Idarubicin—breast cancer	0.0113	0.0457	CbGbCtD
Methotrexate—ABCC10—Gemcitabine—breast cancer	0.0111	0.0449	CbGbCtD
Methotrexate—ALB—breast cancer	0.0108	0.0485	CbGaD
Methotrexate—ABCB1—breast cancer	0.0103	0.0463	CbGaD
Methotrexate—SLCO1A2—Chlorambucil—breast cancer	0.0101	0.0408	CbGbCtD
Methotrexate—ABCC10—Paclitaxel—breast cancer	0.01	0.0406	CbGbCtD
Methotrexate—ABCC10—Docetaxel—breast cancer	0.00724	0.0293	CbGbCtD
Methotrexate—ABCC3—Fluorouracil—breast cancer	0.00596	0.0242	CbGbCtD
Methotrexate—SLCO1B3—Paclitaxel—breast cancer	0.00559	0.0227	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—breast cancer	0.0054	0.0219	CbGbCtD
Methotrexate—ABCC1—Mitoxantrone—breast cancer	0.00484	0.0196	CbGbCtD
Methotrexate—SLC22A7—Fluorouracil—breast cancer	0.00466	0.0189	CbGbCtD
Methotrexate—ABCC4—Fluorouracil—breast cancer	0.00455	0.0185	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—breast cancer	0.00404	0.0164	CbGbCtD
Methotrexate—ABCC1—Epirubicin—breast cancer	0.00392	0.0159	CbGbCtD
Methotrexate—ABCC1—Paclitaxel—breast cancer	0.00387	0.0157	CbGbCtD
Methotrexate—ABCC1—Irinotecan—breast cancer	0.00381	0.0155	CbGbCtD
Methotrexate—ABCC2—Tamoxifen—breast cancer	0.00368	0.0149	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—breast cancer	0.00356	0.0144	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—breast cancer	0.00339	0.0138	CbGbCtD
Methotrexate—ABCC1—Vinblastine—breast cancer	0.00339	0.0137	CbGbCtD
Methotrexate—ABCG2—Tamoxifen—breast cancer	0.00332	0.0135	CbGbCtD
Methotrexate—ABCB1—Toremifene—breast cancer	0.00328	0.0133	CbGbCtD
Methotrexate—ABCG2—Mitoxantrone—breast cancer	0.00324	0.0131	CbGbCtD
Methotrexate—SLCO1B1—Irinotecan—breast cancer	0.00321	0.013	CbGbCtD
Methotrexate—ABCC2—Paclitaxel—breast cancer	0.00286	0.0116	CbGbCtD
Methotrexate—ABCC2—Irinotecan—breast cancer	0.00282	0.0114	CbGbCtD
Methotrexate—ABCC1—Docetaxel—breast cancer	0.00279	0.0113	CbGbCtD
Methotrexate—ABCC2—Carboplatin—breast cancer	0.00269	0.0109	CbGbCtD
Methotrexate—ABCG2—Paclitaxel—breast cancer	0.00259	0.0105	CbGbCtD
Methotrexate—ABCG2—Irinotecan—breast cancer	0.00255	0.0103	CbGbCtD
Methotrexate—ABCC2—Vinblastine—breast cancer	0.00251	0.0102	CbGbCtD
Methotrexate—ABCG2—Fluorouracil—breast cancer	0.00245	0.00993	CbGbCtD
Methotrexate—ABCG2—Carboplatin—breast cancer	0.00243	0.00987	CbGbCtD
Methotrexate—ABCB1—Lapatinib—breast cancer	0.00239	0.0097	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—breast cancer	0.00208	0.00844	CbGbCtD
Methotrexate—ABCC2—Docetaxel—breast cancer	0.00207	0.00839	CbGbCtD
Methotrexate—ABCG2—Docetaxel—breast cancer	0.00187	0.00758	CbGbCtD
Methotrexate—ALB—Irinotecan—breast cancer	0.00176	0.00713	CbGbCtD
Methotrexate—ALB—Fluorouracil—breast cancer	0.00169	0.00684	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—breast cancer	0.00154	0.00625	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—breast cancer	0.00139	0.00565	CbGbCtD
Methotrexate—ABCB1—Vinorelbine—breast cancer	0.00133	0.00538	CbGbCtD
Methotrexate—ABCB1—Tamoxifen—breast cancer	0.0012	0.00486	CbGbCtD
Methotrexate—ABCB1—Mitoxantrone—breast cancer	0.00117	0.00474	CbGbCtD
Methotrexate—ABCB1—Gemcitabine—breast cancer	0.00103	0.00418	CbGbCtD
Methotrexate—ABCB1—Paclitaxel—breast cancer	0.000933	0.00378	CbGbCtD
Methotrexate—ABCB1—Irinotecan—breast cancer	0.00092	0.00373	CbGbCtD
Methotrexate—FOLR1—mammary gland—breast cancer	0.000853	0.0242	CbGeAlD
Methotrexate—ABCB1—Vinblastine—breast cancer	0.000818	0.00332	CbGbCtD
Methotrexate—ABCC11—mammary gland—breast cancer	0.000818	0.0232	CbGeAlD
Methotrexate—SLC19A1—mammary gland—breast cancer	0.000748	0.0212	CbGeAlD
Methotrexate—FOLR1—nipple—breast cancer	0.000706	0.02	CbGeAlD
Methotrexate—ABCB1—Docetaxel—breast cancer	0.000674	0.00273	CbGbCtD
Methotrexate—Tetrahydrofolic acid—SHMT1—breast cancer	0.000593	0.294	CrCbGaD
Methotrexate—ABCC11—embryo—breast cancer	0.000558	0.0158	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—breast cancer	0.000503	0.00204	CbGbCtD
Methotrexate—ATIC—mammary gland—breast cancer	0.000482	0.0137	CbGeAlD
Methotrexate—FOLR1—epithelium—breast cancer	0.000475	0.0135	CbGeAlD
Methotrexate—GGH—nipple—breast cancer	0.000469	0.0133	CbGeAlD
Methotrexate—FOLR1—endometrium—breast cancer	0.000426	0.0121	CbGeAlD
Methotrexate—SLCO4C1—nipple—breast cancer	0.000416	0.0118	CbGeAlD
Methotrexate—FPGS—nipple—breast cancer	0.000412	0.0117	CbGeAlD
Methotrexate—FOLR1—uterus—breast cancer	0.000393	0.0111	CbGeAlD
Methotrexate—FOLR1—pituitary gland—breast cancer	0.000386	0.0109	CbGeAlD
Methotrexate—MTHFR—mammary gland—breast cancer	0.000358	0.0102	CbGeAlD
Methotrexate—FOLR1—female reproductive system—breast cancer	0.000353	0.01	CbGeAlD
Methotrexate—ABCC11—female reproductive system—breast cancer	0.000338	0.0096	CbGeAlD
Methotrexate—SLC19A1—adipose tissue—breast cancer	0.000337	0.00955	CbGeAlD
Methotrexate—ATIC—embryo—breast cancer	0.000329	0.00933	CbGeAlD
Methotrexate—FOLR1—female gonad—breast cancer	0.000321	0.00911	CbGeAlD
Methotrexate—PGD—mammary gland—breast cancer	0.000311	0.00883	CbGeAlD
Methotrexate—SLC19A1—female reproductive system—breast cancer	0.000309	0.00878	CbGeAlD
Methotrexate—ABCC11—female gonad—breast cancer	0.000308	0.00874	CbGeAlD
Methotrexate—Tetrahydrofolic acid—MTR—breast cancer	0.000303	0.15	CrCbGaD
Methotrexate—SLC19A1—adrenal gland—breast cancer	0.000302	0.00857	CbGeAlD
Methotrexate—GGH—skin of body—breast cancer	0.0003	0.00852	CbGeAlD
Methotrexate—FOLR1—endocrine gland—breast cancer	0.000299	0.00847	CbGeAlD
Methotrexate—SLCO3A1—nipple—breast cancer	0.000292	0.00827	CbGeAlD
Methotrexate—ABCC11—endocrine gland—breast cancer	0.000286	0.00812	CbGeAlD
Methotrexate—GGH—endometrium—breast cancer	0.000283	0.00803	CbGeAlD
Methotrexate—SLCO1B1—mammary gland—breast cancer	0.000283	0.00802	CbGeAlD
Methotrexate—ATIC—epithelium—breast cancer	0.000268	0.00762	CbGeAlD
Methotrexate—DHFR—nipple—breast cancer	0.000268	0.0076	CbGeAlD
Methotrexate—Raltitrexed—TYMS—breast cancer	0.000267	0.132	CrCbGaD
Methotrexate—FPGS—skin of body—breast cancer	0.000264	0.00749	CbGeAlD
Methotrexate—SLC19A1—endocrine gland—breast cancer	0.000262	0.00743	CbGeAlD
Methotrexate—GGH—uterus—breast cancer	0.000261	0.0074	CbGeAlD
Methotrexate—SLC46A1—pituitary gland—breast cancer	0.00026	0.00739	CbGeAlD
Methotrexate—PGD—nipple—breast cancer	0.000257	0.0073	CbGeAlD
Methotrexate—GGH—pituitary gland—breast cancer	0.000256	0.00727	CbGeAlD
Methotrexate—ATIC—skin of body—breast cancer	0.000255	0.00724	CbGeAlD
Methotrexate—GGH—adipose tissue—breast cancer	0.000255	0.00724	CbGeAlD
Methotrexate—SLCO4C1—endometrium—breast cancer	0.000251	0.00712	CbGeAlD
Methotrexate—FPGS—endometrium—breast cancer	0.000249	0.00706	CbGeAlD
Methotrexate—TYMS—Docetaxel—Paclitaxel—breast cancer	0.00024	0.226	CbGdCrCtD
Methotrexate—TYMS—Gefitinib—Lapatinib—breast cancer	0.000236	0.222	CbGdCrCtD
Methotrexate—GGH—female reproductive system—breast cancer	0.000235	0.00665	CbGeAlD
Methotrexate—SLC46A1—adrenal gland—breast cancer	0.000233	0.0066	CbGeAlD
Methotrexate—GGH—adrenal gland—breast cancer	0.000229	0.00649	CbGeAlD
Methotrexate—ALB—mammary gland—breast cancer	0.000229	0.00649	CbGeAlD
Methotrexate—AOX1—nipple—breast cancer	0.000227	0.00643	CbGeAlD
Methotrexate—FPGS—pituitary gland—breast cancer	0.000225	0.00639	CbGeAlD
Methotrexate—FPGS—adipose tissue—breast cancer	0.000224	0.00636	CbGeAlD
Methotrexate—ATIC—uterus—breast cancer	0.000222	0.00629	CbGeAlD
Methotrexate—GGH—bone marrow—breast cancer	0.000221	0.00628	CbGeAlD
Methotrexate—DHFR—embryo—breast cancer	0.000221	0.00627	CbGeAlD
Methotrexate—SLCO1B3—pituitary gland—breast cancer	0.000221	0.00627	CbGeAlD
Methotrexate—ABCC10—nipple—breast cancer	0.000221	0.00626	CbGeAlD
Methotrexate—ATIC—adipose tissue—breast cancer	0.000217	0.00616	CbGeAlD
Methotrexate—SLC46A1—female gonad—breast cancer	0.000217	0.00616	CbGeAlD
Methotrexate—GGH—female gonad—breast cancer	0.000213	0.00606	CbGeAlD
Methotrexate—FPGS—female reproductive system—breast cancer	0.000206	0.00585	CbGeAlD
Methotrexate—Pralatrexate—TYMS—breast cancer	0.000202	0.1	CrCbGaD
Methotrexate—Leucovorin—TYMS—breast cancer	0.000202	0.1	CrCbGaD
Methotrexate—SLC46A1—endocrine gland—breast cancer	0.000202	0.00572	CbGeAlD
Methotrexate—FPGS—adrenal gland—breast cancer	0.000201	0.00571	CbGeAlD
Methotrexate—ATIC—female reproductive system—breast cancer	0.000199	0.00566	CbGeAlD
Methotrexate—GGH—endocrine gland—breast cancer	0.000198	0.00563	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—breast cancer	0.000196	0.00557	CbGeAlD
Methotrexate—ATIC—adrenal gland—breast cancer	0.000195	0.00552	CbGeAlD
Methotrexate—FPGS—female gonad—breast cancer	0.000188	0.00532	CbGeAlD
Methotrexate—ATIC—female gonad—breast cancer	0.000181	0.00515	CbGeAlD
Methotrexate—SLCO1C1—pituitary gland—breast cancer	0.000181	0.00514	CbGeAlD
Methotrexate—SLC19A1—lymph node—breast cancer	0.000181	0.00514	CbGeAlD
Methotrexate—SLCO1C1—adipose tissue—breast cancer	0.00018	0.00512	CbGeAlD
Methotrexate—FPGS—endocrine gland—breast cancer	0.000174	0.00495	CbGeAlD
Methotrexate—TYMS—skin of body—breast cancer	0.000173	0.00491	CbGeAlD
Methotrexate—SLCO1B3—endocrine gland—breast cancer	0.000171	0.00485	CbGeAlD
Methotrexate—ATIC—endocrine gland—breast cancer	0.000169	0.00479	CbGeAlD
Methotrexate—PGD—skin of body—breast cancer	0.000165	0.00468	CbGeAlD
Methotrexate—TYMS—endometrium—breast cancer	0.000163	0.00463	CbGeAlD
Methotrexate—Pemetrexed—TYMS—breast cancer	0.000162	0.0802	CrCbGaD
Methotrexate—SLC16A1—epithelium—breast cancer	0.000162	0.00459	CbGeAlD
Methotrexate—DHFR—endometrium—breast cancer	0.000162	0.00459	CbGeAlD
Methotrexate—MTHFR—adipose tissue—breast cancer	0.000161	0.00458	CbGeAlD
Methotrexate—SLC22A11—female reproductive system—breast cancer	0.000161	0.00457	CbGeAlD
Methotrexate—SLCO3A1—pituitary gland—breast cancer	0.000159	0.00452	CbGeAlD
Methotrexate—SLCO3A1—adipose tissue—breast cancer	0.000159	0.0045	CbGeAlD
Methotrexate—ABCC1—nipple—breast cancer	0.000156	0.00443	CbGeAlD
Methotrexate—PGD—endometrium—breast cancer	0.000155	0.00441	CbGeAlD
Methotrexate—DHFR—uterus—breast cancer	0.000149	0.00423	CbGeAlD
Methotrexate—MTHFR—female reproductive system—breast cancer	0.000148	0.00421	CbGeAlD
Methotrexate—TYMS—adipose tissue—breast cancer	0.000147	0.00418	CbGeAlD
Methotrexate—DHFR—pituitary gland—breast cancer	0.000146	0.00415	CbGeAlD
Methotrexate—SLCO3A1—female reproductive system—breast cancer	0.000146	0.00414	CbGeAlD
Methotrexate—DHFR—adipose tissue—breast cancer	0.000146	0.00413	CbGeAlD
Methotrexate—SLC16A1—endometrium—breast cancer	0.000145	0.00412	CbGeAlD
Methotrexate—MTHFR—adrenal gland—breast cancer	0.000145	0.0041	CbGeAlD
Methotrexate—PGD—uterus—breast cancer	0.000143	0.00406	CbGeAlD
Methotrexate—SLCO3A1—adrenal gland—breast cancer	0.000142	0.00404	CbGeAlD
Methotrexate—PGD—pituitary gland—breast cancer	0.000141	0.00399	CbGeAlD
Methotrexate—SLCO1C1—endocrine gland—breast cancer	0.00014	0.00398	CbGeAlD
Methotrexate—PGD—adipose tissue—breast cancer	0.00014	0.00397	CbGeAlD
Methotrexate—SLC46A1—lymph node—breast cancer	0.000139	0.00396	CbGeAlD
Methotrexate—GGH—lymph node—breast cancer	0.000137	0.00389	CbGeAlD
Methotrexate—AOX1—endometrium—breast cancer	0.000137	0.00388	CbGeAlD
Methotrexate—SLC22A11—endocrine gland—breast cancer	0.000136	0.00387	CbGeAlD
Methotrexate—TYMS—female reproductive system—breast cancer	0.000135	0.00384	CbGeAlD
Methotrexate—MTHFR—female gonad—breast cancer	0.000135	0.00383	CbGeAlD
Methotrexate—DHFR—female reproductive system—breast cancer	0.000134	0.0038	CbGeAlD
Methotrexate—SLC16A1—uterus—breast cancer	0.000134	0.00379	CbGeAlD
Methotrexate—ABCC10—endometrium—breast cancer	0.000133	0.00378	CbGeAlD
Methotrexate—SLC22A7—endocrine gland—breast cancer	0.000133	0.00377	CbGeAlD
Methotrexate—SLCO3A1—female gonad—breast cancer	0.000133	0.00377	CbGeAlD
Methotrexate—TYMS—adrenal gland—breast cancer	0.000132	0.00374	CbGeAlD
Methotrexate—SLC16A1—pituitary gland—breast cancer	0.000131	0.00373	CbGeAlD
Methotrexate—SLC16A1—adipose tissue—breast cancer	0.000131	0.00371	CbGeAlD
Methotrexate—DHFR—adrenal gland—breast cancer	0.000131	0.00371	CbGeAlD
Methotrexate—PGD—female reproductive system—breast cancer	0.000129	0.00365	CbGeAlD
Methotrexate—TYMS—bone marrow—breast cancer	0.000128	0.00362	CbGeAlD
Methotrexate—DHFR—bone marrow—breast cancer	0.000126	0.00359	CbGeAlD
Methotrexate—AOX1—uterus—breast cancer	0.000126	0.00358	CbGeAlD
Methotrexate—PGD—adrenal gland—breast cancer	0.000126	0.00356	CbGeAlD
Methotrexate—MTHFR—endocrine gland—breast cancer	0.000125	0.00356	CbGeAlD
Methotrexate—AOX1—pituitary gland—breast cancer	0.000124	0.00352	CbGeAlD
Methotrexate—SLCO3A1—endocrine gland—breast cancer	0.000123	0.0035	CbGeAlD
Methotrexate—AOX1—adipose tissue—breast cancer	0.000123	0.0035	CbGeAlD
Methotrexate—TYMS—female gonad—breast cancer	0.000123	0.00349	CbGeAlD
Methotrexate—ABCC10—uterus—breast cancer	0.000123	0.00348	CbGeAlD
Methotrexate—DHFR—female gonad—breast cancer	0.000122	0.00346	CbGeAlD
Methotrexate—PGD—bone marrow—breast cancer	0.000122	0.00345	CbGeAlD
Methotrexate—ABCC3—adipose tissue—breast cancer	0.000121	0.00342	CbGeAlD
Methotrexate—FPGS—lymph node—breast cancer	0.000121	0.00342	CbGeAlD
Methotrexate—ABCC10—pituitary gland—breast cancer	0.000121	0.00342	CbGeAlD
Methotrexate—SLC16A1—female reproductive system—breast cancer	0.00012	0.00341	CbGeAlD
Methotrexate—ABCC10—adipose tissue—breast cancer	0.00012	0.00341	CbGeAlD
Methotrexate—TYMS—Paclitaxel—Docetaxel—breast cancer	0.00012	0.113	CbGdCrCtD
Methotrexate—SLC16A1—adrenal gland—breast cancer	0.000117	0.00333	CbGeAlD
Methotrexate—PGD—female gonad—breast cancer	0.000117	0.00332	CbGeAlD
Methotrexate—SLCO1B1—female reproductive system—breast cancer	0.000117	0.00332	CbGeAlD
Methotrexate—ATIC—lymph node—breast cancer	0.000117	0.00331	CbGeAlD
Methotrexate—TYMS—endocrine gland—breast cancer	0.000114	0.00325	CbGeAlD
Methotrexate—AOX1—female reproductive system—breast cancer	0.000113	0.00322	CbGeAlD
Methotrexate—DHFR—endocrine gland—breast cancer	0.000113	0.00322	CbGeAlD
Methotrexate—ABCC3—female reproductive system—breast cancer	0.000111	0.00315	CbGeAlD
Methotrexate—AOX1—adrenal gland—breast cancer	0.000111	0.00314	CbGeAlD
Methotrexate—ABCC10—female reproductive system—breast cancer	0.00011	0.00313	CbGeAlD
Methotrexate—SLC16A1—female gonad—breast cancer	0.000109	0.0031	CbGeAlD
Methotrexate—PGD—endocrine gland—breast cancer	0.000109	0.00309	CbGeAlD
Methotrexate—ABCC3—adrenal gland—breast cancer	0.000108	0.00307	CbGeAlD
Methotrexate—ABCC10—adrenal gland—breast cancer	0.000108	0.00306	CbGeAlD
Methotrexate—ABCC10—bone marrow—breast cancer	0.000104	0.00296	CbGeAlD
Methotrexate—Folic Acid—MTHFR—breast cancer	0.000104	0.0514	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—breast cancer	0.000104	0.0514	CrCbGaD
Methotrexate—AOX1—female gonad—breast cancer	0.000103	0.00293	CbGeAlD
Methotrexate—ABCC4—uterus—breast cancer	0.000102	0.00289	CbGeAlD
Methotrexate—SLC16A1—endocrine gland—breast cancer	0.000102	0.00289	CbGeAlD
Methotrexate—ABCC3—female gonad—breast cancer	0.000101	0.00286	CbGeAlD
Methotrexate—ABCC10—female gonad—breast cancer	0.0001	0.00285	CbGeAlD
Methotrexate—ABCC4—adipose tissue—breast cancer	9.96e-05	0.00283	CbGeAlD
Methotrexate—SLCO1B1—endocrine gland—breast cancer	9.89e-05	0.00281	CbGeAlD
Methotrexate—SLCO1C1—lymph node—breast cancer	9.7e-05	0.00275	CbGeAlD
Methotrexate—AOX1—endocrine gland—breast cancer	9.6e-05	0.00272	CbGeAlD
Methotrexate—ABCC1—endometrium—breast cancer	9.43e-05	0.00267	CbGeAlD
Methotrexate—ABCC3—endocrine gland—breast cancer	9.39e-05	0.00266	CbGeAlD
Methotrexate—ABCC10—endocrine gland—breast cancer	9.34e-05	0.00265	CbGeAlD
Methotrexate—ALB—adrenal gland—breast cancer	9.23e-05	0.00262	CbGeAlD
Methotrexate—ABCC4—female reproductive system—breast cancer	9.16e-05	0.0026	CbGeAlD
Methotrexate—ABCC4—adrenal gland—breast cancer	8.94e-05	0.00254	CbGeAlD
Methotrexate—ABCC2—female reproductive system—breast cancer	8.86e-05	0.00251	CbGeAlD
Methotrexate—ABCC1—uterus—breast cancer	8.69e-05	0.00246	CbGeAlD
Methotrexate—MTHFR—lymph node—breast cancer	8.67e-05	0.00246	CbGeAlD
Methotrexate—ABCC2—adrenal gland—breast cancer	8.65e-05	0.00245	CbGeAlD
Methotrexate—ABCC4—bone marrow—breast cancer	8.65e-05	0.00245	CbGeAlD
Methotrexate—SLCO3A1—lymph node—breast cancer	8.53e-05	0.00242	CbGeAlD
Methotrexate—ABCC1—pituitary gland—breast cancer	8.53e-05	0.00242	CbGeAlD
Methotrexate—ABCC1—adipose tissue—breast cancer	8.49e-05	0.00241	CbGeAlD
Methotrexate—ABCC4—female gonad—breast cancer	8.33e-05	0.00236	CbGeAlD
Methotrexate—TYMS—Vincristine—Vinorelbine—breast cancer	8.24e-05	0.0775	CbGdCrCtD
Methotrexate—SLCO1A2—endocrine gland—breast cancer	8.05e-05	0.00228	CbGeAlD
Methotrexate—Folic Acid—ABCG2—breast cancer	7.94e-05	0.0394	CrCbGaD
Methotrexate—TYMS—lymph node—breast cancer	7.91e-05	0.00224	CbGeAlD
Methotrexate—DHFR—lymph node—breast cancer	7.83e-05	0.00222	CbGeAlD
Methotrexate—ABCG2—endometrium—breast cancer	7.8e-05	0.00221	CbGeAlD
Methotrexate—ABCC4—endocrine gland—breast cancer	7.75e-05	0.0022	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vinblastine—breast cancer	7.71e-05	0.0725	CbGdCrCtD
Methotrexate—ABCC1—adrenal gland—breast cancer	7.62e-05	0.00216	CbGeAlD
Methotrexate—PGD—lymph node—breast cancer	7.53e-05	0.00214	CbGeAlD
Methotrexate—ABCC2—endocrine gland—breast cancer	7.5e-05	0.00213	CbGeAlD
Methotrexate—ABCG2—uterus—breast cancer	7.19e-05	0.00204	CbGeAlD
Methotrexate—ABCC1—female gonad—breast cancer	7.1e-05	0.00202	CbGeAlD
Methotrexate—ABCG2—pituitary gland—breast cancer	7.06e-05	0.002	CbGeAlD
Methotrexate—ABCG2—adipose tissue—breast cancer	7.03e-05	0.002	CbGeAlD
Methotrexate—SLC16A1—lymph node—breast cancer	7.03e-05	0.00199	CbGeAlD
Methotrexate—AOX1—lymph node—breast cancer	6.63e-05	0.00188	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vinorelbine—breast cancer	6.63e-05	0.0623	CbGdCrCtD
Methotrexate—TYMS—Vincristine—Vinblastine—breast cancer	6.59e-05	0.062	CbGdCrCtD
Methotrexate—ABCC3—lymph node—breast cancer	6.49e-05	0.00184	CbGeAlD
Methotrexate—ABCC10—lymph node—breast cancer	6.46e-05	0.00183	CbGeAlD
Methotrexate—ABCG2—adrenal gland—breast cancer	6.31e-05	0.00179	CbGeAlD
Methotrexate—ABCG2—bone marrow—breast cancer	6.1e-05	0.00173	CbGeAlD
Methotrexate—ABCG2—female gonad—breast cancer	5.88e-05	0.00167	CbGeAlD
Methotrexate—ALB—lymph node—breast cancer	5.53e-05	0.00157	CbGeAlD
Methotrexate—ABCC4—lymph node—breast cancer	5.36e-05	0.00152	CbGeAlD
Methotrexate—TYMS—Clobetasol propionate—Fluoxymesterone—breast cancer	5.31e-05	0.0499	CbGdCrCtD
Methotrexate—ABCB1—embryo—breast cancer	5.26e-05	0.00149	CbGeAlD
Methotrexate—ABCC2—lymph node—breast cancer	5.19e-05	0.00147	CbGeAlD
Methotrexate—TYMS—Triamcinolone—Fluoxymesterone—breast cancer	5.18e-05	0.0488	CbGdCrCtD
Methotrexate—ABCC1—lymph node—breast cancer	4.57e-05	0.0013	CbGeAlD
Methotrexate—ABCB1—epithelium—breast cancer	4.29e-05	0.00122	CbGeAlD
Methotrexate—TYMS—Danazol—Fluoxymesterone—breast cancer	4.01e-05	0.0378	CbGdCrCtD
Methotrexate—ABCB1—endometrium—breast cancer	3.85e-05	0.00109	CbGeAlD
Methotrexate—ABCG2—lymph node—breast cancer	3.78e-05	0.00107	CbGeAlD
Methotrexate—ABCB1—uterus—breast cancer	3.55e-05	0.00101	CbGeAlD
Methotrexate—ABCB1—pituitary gland—breast cancer	3.48e-05	0.000988	CbGeAlD
Methotrexate—ABCB1—adipose tissue—breast cancer	3.47e-05	0.000984	CbGeAlD
Methotrexate—ABCB1—female reproductive system—breast cancer	3.19e-05	0.000904	CbGeAlD
Methotrexate—ABCB1—adrenal gland—breast cancer	3.11e-05	0.000883	CbGeAlD
Methotrexate—TYMS—Azacitidine—Gemcitabine—breast cancer	3.1e-05	0.0292	CbGdCrCtD
Methotrexate—ABCB1—bone marrow—breast cancer	3.01e-05	0.000854	CbGeAlD
Methotrexate—ABCB1—female gonad—breast cancer	2.9e-05	0.000823	CbGeAlD
Methotrexate—ABCB1—endocrine gland—breast cancer	2.7e-05	0.000765	CbGeAlD
Methotrexate—ABCB1—lymph node—breast cancer	1.86e-05	0.000529	CbGeAlD
Methotrexate—Pneumonia—Doxorubicin—breast cancer	9.32e-06	0.000105	CcSEcCtD
Methotrexate—Nervous system disorder—Docetaxel—breast cancer	9.28e-06	0.000105	CcSEcCtD
Methotrexate—Pruritus—Fluorouracil—breast cancer	9.28e-06	0.000104	CcSEcCtD
Methotrexate—Thrombocytopenia—Docetaxel—breast cancer	9.27e-06	0.000104	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—breast cancer	9.26e-06	0.000104	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—breast cancer	9.26e-06	0.000104	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—breast cancer	9.26e-06	0.000104	CcSEcCtD
Methotrexate—Confusional state—Capecitabine—breast cancer	9.24e-06	0.000104	CcSEcCtD
Methotrexate—Feeling abnormal—Paclitaxel—breast cancer	9.2e-06	0.000104	CcSEcCtD
Methotrexate—Skin disorder—Docetaxel—breast cancer	9.2e-06	0.000104	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—breast cancer	9.18e-06	0.000103	CcSEcCtD
Methotrexate—Gastrointestinal pain—Paclitaxel—breast cancer	9.13e-06	0.000103	CcSEcCtD
Methotrexate—Diarrhoea—Gemcitabine—breast cancer	9.13e-06	0.000103	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—breast cancer	9.11e-06	0.000103	CcSEcCtD
Methotrexate—Infection—Capecitabine—breast cancer	9.11e-06	0.000102	CcSEcCtD
Methotrexate—Dizziness—Irinotecan—breast cancer	9.06e-06	0.000102	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—breast cancer	9.03e-06	0.000102	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—breast cancer	9.03e-06	0.000102	CcSEcCtD
Methotrexate—Anorexia—Docetaxel—breast cancer	9.02e-06	0.000102	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—breast cancer	9e-06	0.000101	CcSEcCtD
Methotrexate—Nervous system disorder—Capecitabine—breast cancer	8.99e-06	0.000101	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—breast cancer	8.99e-06	0.000101	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—breast cancer	8.99e-06	0.000101	CcSEcCtD
Methotrexate—Diarrhoea—Fluorouracil—breast cancer	8.97e-06	0.000101	CcSEcCtD
Methotrexate—Thrombocytopenia—Capecitabine—breast cancer	8.97e-06	0.000101	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—breast cancer	8.92e-06	0.0001	CcSEcCtD
Methotrexate—Skin disorder—Capecitabine—breast cancer	8.9e-06	0.0001	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—breast cancer	8.88e-06	0.0001	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—breast cancer	8.88e-06	9.99e-05	CcSEcCtD
Methotrexate—Urticaria—Paclitaxel—breast cancer	8.87e-06	9.99e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Capecitabine—breast cancer	8.86e-06	9.97e-05	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—breast cancer	8.85e-06	9.96e-05	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—breast cancer	8.83e-06	9.94e-05	CcSEcCtD
Methotrexate—Abdominal pain—Paclitaxel—breast cancer	8.83e-06	9.94e-05	CcSEcCtD
Methotrexate—Body temperature increased—Paclitaxel—breast cancer	8.83e-06	9.94e-05	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—breast cancer	8.81e-06	9.92e-05	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—breast cancer	8.76e-06	9.86e-05	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—breast cancer	8.74e-06	9.84e-05	CcSEcCtD
Methotrexate—Anorexia—Capecitabine—breast cancer	8.74e-06	9.83e-05	CcSEcCtD
Methotrexate—Vomiting—Mitoxantrone—breast cancer	8.71e-06	9.8e-05	CcSEcCtD
Methotrexate—Vomiting—Irinotecan—breast cancer	8.71e-06	9.8e-05	CcSEcCtD
Methotrexate—Dizziness—Fluorouracil—breast cancer	8.67e-06	9.76e-05	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—breast cancer	8.66e-06	9.75e-05	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—breast cancer	8.64e-06	9.73e-05	CcSEcCtD
Methotrexate—Rash—Irinotecan—breast cancer	8.63e-06	9.72e-05	CcSEcCtD
Methotrexate—Rash—Mitoxantrone—breast cancer	8.63e-06	9.72e-05	CcSEcCtD
Methotrexate—Dermatitis—Mitoxantrone—breast cancer	8.63e-06	9.71e-05	CcSEcCtD
Methotrexate—Dermatitis—Irinotecan—breast cancer	8.63e-06	9.71e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—breast cancer	8.62e-06	9.71e-05	CcSEcCtD
Methotrexate—Headache—Mitoxantrone—breast cancer	8.58e-06	9.66e-05	CcSEcCtD
Methotrexate—Headache—Irinotecan—breast cancer	8.58e-06	9.66e-05	CcSEcCtD
Methotrexate—Hypotension—Capecitabine—breast cancer	8.56e-06	9.64e-05	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—breast cancer	8.56e-06	9.64e-05	CcSEcCtD
Methotrexate—Paraesthesia—Docetaxel—breast cancer	8.5e-06	9.57e-05	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—breast cancer	8.5e-06	9.57e-05	CcSEcCtD
Methotrexate—Vomiting—Gemcitabine—breast cancer	8.48e-06	9.55e-05	CcSEcCtD
Methotrexate—Dyspnoea—Docetaxel—breast cancer	8.44e-06	9.5e-05	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—breast cancer	8.42e-06	9.47e-05	CcSEcCtD
Methotrexate—Rash—Gemcitabine—breast cancer	8.41e-06	9.47e-05	CcSEcCtD
Methotrexate—Dermatitis—Gemcitabine—breast cancer	8.4e-06	9.46e-05	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—breast cancer	8.4e-06	9.45e-05	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—breast cancer	8.38e-06	9.43e-05	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—breast cancer	8.36e-06	9.41e-05	CcSEcCtD
Methotrexate—Headache—Gemcitabine—breast cancer	8.36e-06	9.41e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Capecitabine—breast cancer	8.35e-06	9.4e-05	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—breast cancer	8.34e-06	9.39e-05	CcSEcCtD
Methotrexate—Vomiting—Fluorouracil—breast cancer	8.34e-06	9.39e-05	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—breast cancer	8.33e-06	9.38e-05	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—breast cancer	8.32e-06	9.36e-05	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—breast cancer	8.32e-06	9.36e-05	CcSEcCtD
Methotrexate—Insomnia—Capecitabine—breast cancer	8.29e-06	9.33e-05	CcSEcCtD
Methotrexate—Rash—Fluorouracil—breast cancer	8.27e-06	9.31e-05	CcSEcCtD
Methotrexate—Dermatitis—Fluorouracil—breast cancer	8.26e-06	9.3e-05	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—breast cancer	8.25e-06	9.29e-05	CcSEcCtD
Methotrexate—Paraesthesia—Capecitabine—breast cancer	8.23e-06	9.26e-05	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—breast cancer	8.23e-06	9.26e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Paclitaxel—breast cancer	8.23e-06	9.26e-05	CcSEcCtD
Methotrexate—Headache—Fluorouracil—breast cancer	8.22e-06	9.25e-05	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—breast cancer	8.21e-06	9.24e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Docetaxel—breast cancer	8.17e-06	9.2e-05	CcSEcCtD
Methotrexate—Dyspnoea—Capecitabine—breast cancer	8.17e-06	9.2e-05	CcSEcCtD
Methotrexate—Fatigue—Docetaxel—breast cancer	8.16e-06	9.19e-05	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—breast cancer	8.15e-06	9.18e-05	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—breast cancer	8.15e-06	9.18e-05	CcSEcCtD
Methotrexate—Nausea—Mitoxantrone—breast cancer	8.13e-06	9.16e-05	CcSEcCtD
Methotrexate—Nausea—Irinotecan—breast cancer	8.13e-06	9.16e-05	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—breast cancer	8.12e-06	9.14e-05	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—breast cancer	8.1e-06	9.12e-05	CcSEcCtD
Methotrexate—Pain—Docetaxel—breast cancer	8.1e-06	9.11e-05	CcSEcCtD
Methotrexate—Dyspepsia—Capecitabine—breast cancer	8.07e-06	9.08e-05	CcSEcCtD
Methotrexate—Chills—Epirubicin—breast cancer	8.06e-06	9.08e-05	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—breast cancer	8.01e-06	9.02e-05	CcSEcCtD
Methotrexate—Asthenia—Paclitaxel—breast cancer	8.01e-06	9.02e-05	CcSEcCtD
Methotrexate—Decreased appetite—Capecitabine—breast cancer	7.97e-06	8.97e-05	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—breast cancer	7.94e-06	8.94e-05	CcSEcCtD
Methotrexate—Nausea—Gemcitabine—breast cancer	7.92e-06	8.92e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Capecitabine—breast cancer	7.91e-06	8.91e-05	CcSEcCtD
Methotrexate—Fatigue—Capecitabine—breast cancer	7.9e-06	8.9e-05	CcSEcCtD
Methotrexate—Pruritus—Paclitaxel—breast cancer	7.9e-06	8.89e-05	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—breast cancer	7.87e-06	8.86e-05	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—breast cancer	7.86e-06	8.85e-05	CcSEcCtD
Methotrexate—Pain—Capecitabine—breast cancer	7.84e-06	8.82e-05	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—breast cancer	7.82e-06	8.81e-05	CcSEcCtD
Methotrexate—Erythema—Epirubicin—breast cancer	7.82e-06	8.81e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Docetaxel—breast cancer	7.8e-06	8.78e-05	CcSEcCtD
Methotrexate—Nausea—Fluorouracil—breast cancer	7.79e-06	8.77e-05	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—breast cancer	7.77e-06	8.75e-05	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—breast cancer	7.75e-06	8.73e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—breast cancer	7.74e-06	8.71e-05	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—breast cancer	7.72e-06	8.69e-05	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—breast cancer	7.66e-06	8.62e-05	CcSEcCtD
Methotrexate—Diarrhoea—Paclitaxel—breast cancer	7.64e-06	8.6e-05	CcSEcCtD
Methotrexate—Back pain—Epirubicin—breast cancer	7.57e-06	8.52e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Capecitabine—breast cancer	7.55e-06	8.5e-05	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—breast cancer	7.54e-06	8.49e-05	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—breast cancer	7.51e-06	8.46e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Capecitabine—breast cancer	7.49e-06	8.44e-05	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—breast cancer	7.49e-06	8.44e-05	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—breast cancer	7.48e-06	8.42e-05	CcSEcCtD
Methotrexate—Body temperature increased—Docetaxel—breast cancer	7.48e-06	8.42e-05	CcSEcCtD
Methotrexate—Chills—Doxorubicin—breast cancer	7.46e-06	8.4e-05	CcSEcCtD
Methotrexate—Dizziness—Paclitaxel—breast cancer	7.39e-06	8.31e-05	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—breast cancer	7.37e-06	8.3e-05	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—breast cancer	7.35e-06	8.27e-05	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—breast cancer	7.29e-06	8.2e-05	CcSEcCtD
Methotrexate—Urticaria—Capecitabine—breast cancer	7.28e-06	8.2e-05	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—breast cancer	7.26e-06	8.17e-05	CcSEcCtD
Methotrexate—Abdominal pain—Capecitabine—breast cancer	7.25e-06	8.16e-05	CcSEcCtD
Methotrexate—Body temperature increased—Capecitabine—breast cancer	7.25e-06	8.16e-05	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—breast cancer	7.24e-06	8.15e-05	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—breast cancer	7.24e-06	8.15e-05	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—breast cancer	7.23e-06	8.14e-05	CcSEcCtD
Methotrexate—Vomiting—Paclitaxel—breast cancer	7.1e-06	7.99e-05	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—breast cancer	7.09e-06	7.98e-05	CcSEcCtD
Methotrexate—Malaise—Epirubicin—breast cancer	7.06e-06	7.94e-05	CcSEcCtD
Methotrexate—Rash—Paclitaxel—breast cancer	7.04e-06	7.93e-05	CcSEcCtD
Methotrexate—Dermatitis—Paclitaxel—breast cancer	7.04e-06	7.92e-05	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—breast cancer	7.03e-06	7.91e-05	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—breast cancer	7e-06	7.88e-05	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—breast cancer	7e-06	7.88e-05	CcSEcCtD
Methotrexate—Headache—Paclitaxel—breast cancer	7e-06	7.88e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Docetaxel—breast cancer	6.97e-06	7.85e-05	CcSEcCtD
Methotrexate—Cough—Epirubicin—breast cancer	6.83e-06	7.69e-05	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—breast cancer	6.82e-06	7.68e-05	CcSEcCtD
Methotrexate—Asthenia—Docetaxel—breast cancer	6.79e-06	7.65e-05	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—breast cancer	6.78e-06	7.63e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Capecitabine—breast cancer	6.75e-06	7.6e-05	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—breast cancer	6.72e-06	7.56e-05	CcSEcCtD
Methotrexate—Pruritus—Docetaxel—breast cancer	6.7e-06	7.54e-05	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—breast cancer	6.69e-06	7.53e-05	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—breast cancer	6.66e-06	7.5e-05	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—breast cancer	6.66e-06	7.5e-05	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—breast cancer	6.66e-06	7.5e-05	CcSEcCtD
Methotrexate—Nausea—Paclitaxel—breast cancer	6.63e-06	7.47e-05	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	6.61e-06	7.45e-05	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—breast cancer	6.58e-06	7.41e-05	CcSEcCtD
Methotrexate—Asthenia—Capecitabine—breast cancer	6.58e-06	7.4e-05	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—breast cancer	6.53e-06	7.35e-05	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—breast cancer	6.5e-06	7.32e-05	CcSEcCtD
Methotrexate—Pruritus—Capecitabine—breast cancer	6.48e-06	7.3e-05	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—breast cancer	6.48e-06	7.29e-05	CcSEcCtD
Methotrexate—Diarrhoea—Docetaxel—breast cancer	6.48e-06	7.29e-05	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—breast cancer	6.44e-06	7.25e-05	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—breast cancer	6.39e-06	7.19e-05	CcSEcCtD
Methotrexate—Infection—Epirubicin—breast cancer	6.34e-06	7.14e-05	CcSEcCtD
Methotrexate—Cough—Doxorubicin—breast cancer	6.32e-06	7.11e-05	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—breast cancer	6.27e-06	7.06e-05	CcSEcCtD
Methotrexate—Diarrhoea—Capecitabine—breast cancer	6.27e-06	7.06e-05	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—breast cancer	6.26e-06	7.05e-05	CcSEcCtD
Methotrexate—Dizziness—Docetaxel—breast cancer	6.26e-06	7.05e-05	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—breast cancer	6.25e-06	7.04e-05	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—breast cancer	6.2e-06	6.98e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—breast cancer	6.17e-06	6.95e-05	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—breast cancer	6.16e-06	6.94e-05	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—breast cancer	6.16e-06	6.94e-05	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—breast cancer	6.16e-06	6.94e-05	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	6.12e-06	6.89e-05	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—breast cancer	6.09e-06	6.85e-05	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—breast cancer	6.09e-06	6.85e-05	CcSEcCtD
Methotrexate—Dizziness—Capecitabine—breast cancer	6.06e-06	6.82e-05	CcSEcCtD
Methotrexate—Vomiting—Docetaxel—breast cancer	6.02e-06	6.78e-05	CcSEcCtD
Methotrexate—Rash—Docetaxel—breast cancer	5.97e-06	6.72e-05	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—breast cancer	5.97e-06	6.72e-05	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—breast cancer	5.96e-06	6.71e-05	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—breast cancer	5.96e-06	6.71e-05	CcSEcCtD
Methotrexate—Headache—Docetaxel—breast cancer	5.93e-06	6.68e-05	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—breast cancer	5.91e-06	6.65e-05	CcSEcCtD
Methotrexate—Infection—Doxorubicin—breast cancer	5.87e-06	6.61e-05	CcSEcCtD
Methotrexate—Vomiting—Capecitabine—breast cancer	5.83e-06	6.56e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—breast cancer	5.82e-06	6.55e-05	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—breast cancer	5.79e-06	6.52e-05	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—breast cancer	5.78e-06	6.51e-05	CcSEcCtD
Methotrexate—Rash—Capecitabine—breast cancer	5.78e-06	6.51e-05	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—breast cancer	5.78e-06	6.5e-05	CcSEcCtD
Methotrexate—Dermatitis—Capecitabine—breast cancer	5.77e-06	6.5e-05	CcSEcCtD
Methotrexate—Headache—Capecitabine—breast cancer	5.74e-06	6.46e-05	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—breast cancer	5.74e-06	6.46e-05	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—breast cancer	5.73e-06	6.45e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—breast cancer	5.71e-06	6.43e-05	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—breast cancer	5.69e-06	6.41e-05	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—breast cancer	5.68e-06	6.39e-05	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—breast cancer	5.63e-06	6.34e-05	CcSEcCtD
Methotrexate—Nausea—Docetaxel—breast cancer	5.62e-06	6.33e-05	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—breast cancer	5.62e-06	6.33e-05	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—breast cancer	5.55e-06	6.25e-05	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—breast cancer	5.52e-06	6.21e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—breast cancer	5.51e-06	6.21e-05	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—breast cancer	5.51e-06	6.2e-05	CcSEcCtD
Methotrexate—Pain—Epirubicin—breast cancer	5.46e-06	6.15e-05	CcSEcCtD
Methotrexate—Nausea—Capecitabine—breast cancer	5.44e-06	6.13e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—breast cancer	5.38e-06	6.06e-05	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—breast cancer	5.34e-06	6.02e-05	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—breast cancer	5.31e-06	5.97e-05	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—breast cancer	5.27e-06	5.93e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—breast cancer	5.26e-06	5.92e-05	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—breast cancer	5.25e-06	5.91e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—breast cancer	5.22e-06	5.88e-05	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—breast cancer	5.2e-06	5.85e-05	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—breast cancer	5.14e-06	5.78e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—breast cancer	5.1e-06	5.74e-05	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—breast cancer	5.09e-06	5.73e-05	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—breast cancer	5.07e-06	5.71e-05	CcSEcCtD
Methotrexate—Pain—Doxorubicin—breast cancer	5.05e-06	5.69e-05	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—breast cancer	5.05e-06	5.68e-05	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—breast cancer	5.05e-06	5.68e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—breast cancer	4.87e-06	5.48e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—breast cancer	4.83e-06	5.44e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—breast cancer	4.7e-06	5.3e-05	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—breast cancer	4.69e-06	5.28e-05	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—breast cancer	4.67e-06	5.26e-05	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—breast cancer	4.67e-06	5.26e-05	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—breast cancer	4.58e-06	5.16e-05	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—breast cancer	4.52e-06	5.09e-05	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—breast cancer	4.37e-06	4.92e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—breast cancer	4.35e-06	4.9e-05	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—breast cancer	4.24e-06	4.77e-05	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—breast cancer	4.22e-06	4.75e-05	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—breast cancer	4.18e-06	4.71e-05	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—breast cancer	4.06e-06	4.57e-05	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—breast cancer	4.04e-06	4.55e-05	CcSEcCtD
Methotrexate—Rash—Epirubicin—breast cancer	4.03e-06	4.53e-05	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—breast cancer	4.02e-06	4.53e-05	CcSEcCtD
Methotrexate—Headache—Epirubicin—breast cancer	4e-06	4.5e-05	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—breast cancer	3.91e-06	4.4e-05	CcSEcCtD
Methotrexate—Nausea—Epirubicin—breast cancer	3.79e-06	4.27e-05	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—breast cancer	3.76e-06	4.23e-05	CcSEcCtD
Methotrexate—Rash—Doxorubicin—breast cancer	3.73e-06	4.19e-05	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—breast cancer	3.72e-06	4.19e-05	CcSEcCtD
Methotrexate—Headache—Doxorubicin—breast cancer	3.7e-06	4.17e-05	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—breast cancer	3.51e-06	3.95e-05	CcSEcCtD
Methotrexate—ABCG2—Metabolism—TYMS—breast cancer	7.78e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	7.75e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—breast cancer	7.75e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—breast cancer	7.75e-07	1.19e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK3—breast cancer	7.75e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—breast cancer	7.72e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NCOR1—breast cancer	7.69e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLA2G4A—breast cancer	7.69e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—breast cancer	7.69e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HPGDS—breast cancer	7.68e-07	1.18e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—breast cancer	7.67e-07	1.17e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGF—breast cancer	7.66e-07	1.17e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—breast cancer	7.65e-07	1.17e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—breast cancer	7.64e-07	1.17e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HBA1—breast cancer	7.63e-07	1.17e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—NOS3—breast cancer	7.62e-07	1.17e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—breast cancer	7.6e-07	1.16e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—breast cancer	7.59e-07	1.16e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.56e-07	1.16e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPINE1—breast cancer	7.56e-07	1.16e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—breast cancer	7.53e-07	1.15e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—breast cancer	7.52e-07	1.15e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	7.5e-07	1.15e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—breast cancer	7.46e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—breast cancer	7.45e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ACHE—breast cancer	7.45e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—DPYD—breast cancer	7.38e-07	1.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MED12—breast cancer	7.38e-07	1.13e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—breast cancer	7.37e-07	1.13e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX1—breast cancer	7.36e-07	1.13e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—breast cancer	7.34e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—breast cancer	7.33e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—breast cancer	7.29e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—breast cancer	7.28e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—breast cancer	7.28e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDOA—breast cancer	7.27e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ERCC2—breast cancer	7.23e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS3—breast cancer	7.21e-07	1.11e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—breast cancer	7.21e-07	1.11e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—breast cancer	7.2e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—breast cancer	7.19e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAV1—breast cancer	7.12e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT2—breast cancer	7.09e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA3—breast cancer	7.05e-07	1.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP17A1—breast cancer	7.05e-07	1.08e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—breast cancer	7.03e-07	1.08e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—breast cancer	7.03e-07	1.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A2—breast cancer	7e-07	1.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS1—breast cancer	6.98e-07	1.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO1—breast cancer	6.98e-07	1.07e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—breast cancer	6.97e-07	1.07e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—breast cancer	6.96e-07	1.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	6.95e-07	1.07e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—breast cancer	6.91e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NOS3—breast cancer	6.87e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CPT1A—breast cancer	6.86e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTR—breast cancer	6.86e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ABCG2—breast cancer	6.86e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2D6—breast cancer	6.85e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAF1—breast cancer	6.82e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—breast cancer	6.81e-07	1.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.81e-07	1.04e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—breast cancer	6.8e-07	1.04e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAV1—breast cancer	6.77e-07	1.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SERPINE1—breast cancer	6.74e-07	1.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HPGDS—breast cancer	6.73e-07	1.03e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOA2—breast cancer	6.72e-07	1.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HBA1—breast cancer	6.69e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—breast cancer	6.66e-07	1.02e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—breast cancer	6.66e-07	1.02e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—breast cancer	6.62e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—breast cancer	6.53e-07	1e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ACHE—breast cancer	6.53e-07	1e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—FASN—breast cancer	6.52e-07	9.99e-06	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—breast cancer	6.5e-07	9.97e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—BCHE—breast cancer	6.49e-07	9.94e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—breast cancer	6.49e-07	9.94e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.47e-07	9.91e-06	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	6.43e-07	9.86e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS3—breast cancer	6.43e-07	9.86e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A5—breast cancer	6.41e-07	9.82e-06	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—breast cancer	6.4e-07	9.8e-06	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—breast cancer	6.37e-07	9.77e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—breast cancer	6.35e-07	9.72e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—breast cancer	6.34e-07	9.71e-06	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	6.33e-07	9.71e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—breast cancer	6.29e-07	9.64e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAV1—breast cancer	6.27e-07	9.61e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—breast cancer	6.26e-07	9.59e-06	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—breast cancer	6.22e-07	9.54e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NQO1—breast cancer	6.19e-07	9.49e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A1—breast cancer	6.19e-07	9.49e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP17A1—breast cancer	6.18e-07	9.47e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—breast cancer	6.17e-07	9.45e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO1—breast cancer	6.12e-07	9.37e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS1—breast cancer	6.12e-07	9.37e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—breast cancer	6.12e-07	9.37e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—breast cancer	6.1e-07	9.35e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAF1—breast cancer	6.08e-07	9.32e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—breast cancer	6.08e-07	9.31e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.06e-07	9.29e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP3A4—breast cancer	6.04e-07	9.25e-06	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—breast cancer	6.03e-07	9.24e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—breast cancer	6.02e-07	9.22e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.01e-07	9.2e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2D6—breast cancer	6e-07	9.19e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NOS3—breast cancer	5.99e-07	9.17e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—breast cancer	5.94e-07	9.1e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—breast cancer	5.94e-07	9.1e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1B1—breast cancer	5.94e-07	9.1e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—breast cancer	5.93e-07	9.08e-06	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—breast cancer	5.92e-07	9.07e-06	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	5.9e-07	9.05e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA2—breast cancer	5.89e-07	9.02e-06	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—breast cancer	5.89e-07	9.02e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—breast cancer	5.88e-07	9.02e-06	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—breast cancer	5.88e-07	9.01e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HSP90AA1—breast cancer	5.82e-07	8.92e-06	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—breast cancer	5.74e-07	8.8e-06	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	5.72e-07	8.77e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—breast cancer	5.71e-07	8.75e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—FASN—breast cancer	5.71e-07	8.75e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—breast cancer	5.7e-07	8.74e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BCHE—breast cancer	5.69e-07	8.71e-06	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—breast cancer	5.66e-07	8.68e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOA1—breast cancer	5.66e-07	8.68e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—breast cancer	5.63e-07	8.63e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A5—breast cancer	5.62e-07	8.61e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STK11—breast cancer	5.58e-07	8.55e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP19A1—breast cancer	5.58e-07	8.55e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—breast cancer	5.57e-07	8.54e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—breast cancer	5.53e-07	8.47e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—breast cancer	5.48e-07	8.4e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—breast cancer	5.47e-07	8.39e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NQO1—breast cancer	5.42e-07	8.31e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A1—breast cancer	5.42e-07	8.31e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—breast cancer	5.42e-07	8.31e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NOS3—breast cancer	5.39e-07	8.25e-06	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—breast cancer	5.36e-07	8.21e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—breast cancer	5.35e-07	8.2e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—breast cancer	5.34e-07	8.18e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP3A4—breast cancer	5.29e-07	8.11e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—breast cancer	5.26e-07	8.07e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.24e-07	8.03e-06	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—breast cancer	5.22e-07	8.01e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1B1—breast cancer	5.2e-07	7.97e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—breast cancer	5.2e-07	7.96e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—COMT—breast cancer	5.19e-07	7.95e-06	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	5.17e-07	7.93e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—breast cancer	5.16e-07	7.91e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—breast cancer	5.14e-07	7.88e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—breast cancer	5.13e-07	7.86e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NOS3—breast cancer	5.12e-07	7.84e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HSP90AA1—breast cancer	5.1e-07	7.82e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMOX1—breast cancer	5.09e-07	7.8e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ITPR1—breast cancer	5.08e-07	7.79e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—breast cancer	5.02e-07	7.69e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—breast cancer	4.97e-07	7.62e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA1—breast cancer	4.96e-07	7.6e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—breast cancer	4.96e-07	7.59e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—breast cancer	4.93e-07	7.55e-06	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—breast cancer	4.92e-07	7.55e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK3—breast cancer	4.92e-07	7.53e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STK11—breast cancer	4.89e-07	7.49e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP19A1—breast cancer	4.89e-07	7.49e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—breast cancer	4.89e-07	7.49e-06	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—breast cancer	4.88e-07	7.48e-06	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—breast cancer	4.81e-07	7.37e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—breast cancer	4.8e-07	7.36e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—breast cancer	4.77e-07	7.32e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—breast cancer	4.77e-07	7.31e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—breast cancer	4.76e-07	7.29e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLA2G4A—breast cancer	4.74e-07	7.27e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—breast cancer	4.74e-07	7.27e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOR1—breast cancer	4.74e-07	7.27e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NOS3—breast cancer	4.74e-07	7.26e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—breast cancer	4.73e-07	7.24e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—breast cancer	4.68e-07	7.17e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—breast cancer	4.67e-07	7.16e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—breast cancer	4.59e-07	7.03e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—COMT—breast cancer	4.55e-07	6.97e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX1—breast cancer	4.54e-07	6.96e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—breast cancer	4.52e-07	6.93e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—breast cancer	4.5e-07	6.89e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMOX1—breast cancer	4.46e-07	6.84e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ERCC2—breast cancer	4.46e-07	6.84e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ITPR1—breast cancer	4.45e-07	6.82e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—breast cancer	4.42e-07	6.77e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK3—breast cancer	4.38e-07	6.72e-06	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—breast cancer	4.38e-07	6.7e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—breast cancer	4.38e-07	6.7e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—breast cancer	4.34e-07	6.64e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—breast cancer	4.3e-07	6.58e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—breast cancer	4.29e-07	6.57e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—breast cancer	4.26e-07	6.53e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—breast cancer	4.25e-07	6.52e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—breast cancer	4.21e-07	6.45e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—breast cancer	4.19e-07	6.43e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—breast cancer	4.17e-07	6.39e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLA2G4A—breast cancer	4.16e-07	6.37e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOR1—breast cancer	4.16e-07	6.37e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—breast cancer	4.16e-07	6.37e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—breast cancer	4.08e-07	6.26e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—breast cancer	4.06e-07	6.22e-06	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—breast cancer	3.98e-07	6.11e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX1—breast cancer	3.98e-07	6.1e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—breast cancer	3.94e-07	6.04e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—breast cancer	3.94e-07	6.04e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—breast cancer	3.93e-07	6.02e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ERCC2—breast cancer	3.91e-07	5.99e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—breast cancer	3.87e-07	5.93e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAV1—breast cancer	3.87e-07	5.93e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—breast cancer	3.82e-07	5.85e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—breast cancer	3.78e-07	5.79e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—breast cancer	3.76e-07	5.76e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.7e-07	5.66e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—breast cancer	3.67e-07	5.63e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—breast cancer	3.62e-07	5.55e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—breast cancer	3.52e-07	5.4e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—breast cancer	3.5e-07	5.37e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAV1—breast cancer	3.39e-07	5.19e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—breast cancer	3.37e-07	5.16e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—breast cancer	3.35e-07	5.13e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—breast cancer	3.32e-07	5.08e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—breast cancer	3.2e-07	4.91e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—breast cancer	3.16e-07	4.84e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—breast cancer	3.1e-07	4.75e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—breast cancer	3.09e-07	4.73e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—breast cancer	3.03e-07	4.64e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—breast cancer	2.96e-07	4.53e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NOS3—breast cancer	2.92e-07	4.48e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—breast cancer	2.88e-07	4.41e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—breast cancer	2.75e-07	4.22e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—breast cancer	2.71e-07	4.16e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—breast cancer	2.7e-07	4.14e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—breast cancer	2.68e-07	4.11e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—breast cancer	2.67e-07	4.1e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—breast cancer	2.67e-07	4.09e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NOS3—breast cancer	2.56e-07	3.93e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—breast cancer	2.48e-07	3.79e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—breast cancer	2.37e-07	3.62e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—breast cancer	2.35e-07	3.61e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—breast cancer	2.34e-07	3.59e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—breast cancer	2.33e-07	3.57e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—breast cancer	2.18e-07	3.34e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—breast cancer	2.04e-07	3.13e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—breast cancer	1.65e-07	2.52e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—breast cancer	1.44e-07	2.21e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—breast cancer	1.34e-07	2.06e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—breast cancer	1.18e-07	1.81e-06	CbGpPWpGaD
